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Abstract
Background: QuantiFERON-TB Gold In Tube (QFT-GIT) is a tool for detecting M. tuberculosis infection. However,
interpretation and utility of serial QFT-GIT testing of pediatric tuberculosis (TB) contacts is not well understood. We
compared TB prevalence between baseline and 6 months follow-up using QFT-GIT and tuberculin skin testing (TST) in
children who were household contacts of adults with pulmonary TB in South Africa, and explored factors associated with
QFT-GIT conversions and reversions.
Method: Prospective study with six month longitudinal follow-up.
Results: Among 270 enrolled pediatric contacts, 196 (73%) underwent 6-month follow-up testing. The 6-month prevalence
estimate of MTB infection in pediatric contacts increased significantly from a baseline of 29% (79/270, 95%CI [24–35]) to
38% (103/270, 95% CI [32–44], p,0.001) using QFT-GIT; prevalence increased from a baseline of 28% (71/254, 95%CI [23–
34]) to 33% (88/263, 95%CI [21–32], p=0.002) using TST. Prevalence estimates were influenced by thresholds for positivity
for TST, but not for QFT-GIT. Among 134 children with a negative or indeterminate baseline QFT-GIT, 24 (18%) converted to
positive at follow-up; conversion rates did not differ significantly when using more stringent thresholds to define QFT-GIT
conversion. Older age .10 years (AOR 8.9 95%CI [1.1–72]) and baseline TST positivity $5 mm (AOR 5.2 95%CI [1.2–23]) were
associated with QFT-GIT conversion. Among 62 children with a positive baseline QFT-GIT, 9 (15%) reverted to negative;
female gender (AOR 18.5 95%CI [1.1–321]; p=0.04] was associated with reversion, while children with baseline positive TST
were less likely to have QFT-GIT reversion (AOR 0.01 95%CI [0.001–0.24]).
Conclusion: Among pediatric contacts of adult household TB cases in South Africa, prevalence estimates of TB infection
increased significantly from baseline to 6 months. Conversions and reversions occurred among pediatric TB contacts using
QFT-GIT, but QFT-GIT conversion rates were less influenced by thresholds used for conversions than were TST conversion
rates.
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Introduction
In the wake of a significant HIV epidemic, South Africa has
experienced a dramatic rise in the incidence of tuberculosis (TB)
[1]. Children are particularly vulnerable, as they have high rates of
progression from latent tuberculosis infection (LTBI) to active TB
disease and are at risk for severe forms of TB disease [2,3]. These
issues underscore the need for early detection and diagnosis of M.
tuberculosis (MTB) infection in children. Childhood tuberculosis is
usually a consequence of recent transmission from an adult with
pulmonary TB [4]. Therefore, early identification of TB infection
among childhood contacts of adults with pulmonary TB may be
important to prevent rapid progression to active TB in TB
endemic settings. Active contact tracing of children who are
household contacts of adult TB cases is currently recommended in
South Africa [5]. However, the optimal test and testing strategy for
detecting TB infection in pediatric contacts is unknown.
Tuberculin skin testing (TST) is the most widely used method
for detecting TB infection, but has limitations. There can be
immunological cross-reactivity between TST reagents and Bacille
Calmette Guerin (BCG) vaccine, thereby complicating the
interpretation of TST results in areas where BCG is administered.
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commercially available QuantiFERON-TB Gold In Tube (QFT-
GIT, Cellestis, Ltd, Carnegie, Australia) and T-SPOT.TB tests
(Oxford Immunotec Limited, Abingdon, United Kingdom), have
the potential to overcome some of TST’s limitations [6]. IGRAs
detect MTB infection by measuring in vitro IFN-c release following
stimulation of lymphocytes with antigens specific to M. tuberculosis,
and offer the theoretical advantage of higher specificity in BCG-
vaccinated populations [6]. In contrast to TST, IGRAs require
only one visit to obtain a result, making them attractive for use in
contact investigations. Some guidelines endorse the use of IGRAs
as alternatives to TST for detection of TB infection, but studies
evaluating IGRA performance in children are lacking [7].
Several issues about the use of IGRAs in pediatric TB contact
investigations remain unresolved. The timing of IGRA conversion
after new infection is not clear, and some have recommended
serial testing when used as part of contact investigations [7]. The
performance of IGRAs in serial testing in children has not been
fully explored, although adult studies suggest high rates of
apparent conversions and reversions [8]. Given potential within-
person variability in test results, the optimal threshold to define
IGRA conversion is unclear, since minor variations around the
diagnostic cut-off points could lead to misclassifications [9]. It is
unclear whether the same cut-off that is used for initial diagnosis of
LTBI ($0.35 IU/ml or $8spots for QFT-GIT and T-SPOT.TB,
respectively) should also be used to define a test conversion on
serial testing [8,9,10].
The yield of serial testing for contact investigations in pediatric
populations after diagnosis of an adult household case in South
Africa and other TB-prevalent settings is unknown. Early
immunologic-based testing of pediatric contacts soon after TB
infection may not allow sufficient time for immunologic responses
to develop, leading to an underestimation of true TB prevalence.
Moreover, there may be ongoing household TB transmission that
would be missed on initial TB investigations. Follow-up TB testing
of pediatric contacts may thus identify additional cases of TB
infection, but the yield of such a strategy in South Africa has not
been fully explored.
We previously reported a high prevalence of MTB infection as
assessed by a single TST (prevalence of 28% using a 5 mm cut-off)
or QFT-GIT test (prevalence 29%), among children in South
Africa who were household contacts of an adult with newly
diagnosed pulmonary TB [11]. We now explore and compare the
yield of performing a 6-month follow-up TST and QFT-GIT in
detecting TB infection among these children. We also examined
the dynamics of TST and QFT-GIT responses on serial testing in
children, and evaluated the impact of using varying thresholds for
defining test conversions.
Methods
Ethics Statement
The study was approved by ethics committees at the University
of the Witwatersrand (Johannesburg, South Africa) and the Johns
Hopkins University School of Medicine (Baltimore, USA). Written
informed parental consent (and assent for children aged $7 years)
was obtained from all participants.
Objectives
We sought to determine the 6-month prevalence of M.
tuberculosis infection among children who were household contacts
of adult pulmonary TB cases, and to compare baseline prevalence
estimates to 6 month testing results. We also sought to compare
the prevalence estimates as determined by two different tests for
TB infection, the TST and QFT-GIT tests, and to identify factors
associated with prevalent pediatric TB infection. We explored the
dynamics of serial testing by exploring different thresholds to
define TST and QFT-GIT conversion, and by examining factors
associated with test conversions and reversions.
Participants
Study methods for baseline TB testing have been described in
detail previously [11]. Briefly, adult pulmonary TB index cases
and children living in Soweto, South Africa between October 2006
and December 2009 were enrolled. Index adult TB cases aged
$18 years who had been diagnosed with pulmonary TB within
the preceding three months and had at least one age-eligible child
in the household were study eligible. Pediatric contacts of enrolled
adult TB index cases were included if they were age $6 months to
#16 years; children were excluded if they had a prior diagnosis or
treatment of active or latent TB.
Description of Procedures
For pediatric contacts, demographic, medical, and TB exposure
and treatment information was collected through interview of the
enrolled parent/guardian. TST and QFT-GIT were performed at
the time of enrollment on all pediatric contacts at the same study
visit; phlebotomy for QFT-GIT was performed immediately after
TST placement. For TST, tuberculin purified protein derivative
(PPD) RT-23 (2 units, Statens Serum Institut, Copenhagen,
Denmark) was injected subcutaneously into the left forearm and
the test was read 48–72 hours later. An induration of $5 mm was
considered a positive TST during the study, as per ATS/CDC/
IDSA TB guidelines for TB contacts [12]. QFT-GIT testing was
performed according to the manufacturer’s instructions [13]. The
QFT-GIT assay included a nil control, mitogen control, and an
antigen tube. All assays were conducted in a single laboratory by
the same trained technician. Following stimulation and centrifu-
gation, harvested plasma specimens were stored at 4uC for up to
28 days prior to ELISA testing. Results were calculated and
interpreted by the assay software as positive, negative, or
indeterminate, according to manufacturer’s instructions [13].
HIV testing using an age-appropriate test was performed at the
baseline visit on pediatric contacts.
Children had a follow-up study evaluation at 6 months after
their initial visit. Interval medical history and TB exposure/
treatment history were obtained through interview with the
parent/guardian. All children received a QFT-GIT at the 6-
month follow-up visit. Children with a baseline positive TST
($5 mm induration) did not have a repeat TST performed.
Children with a negative baseline TST (,5 mm) had a repeat
TST performed. A TST of $5 mm induration at 6 month follow-
up was considered positive during study implementation. Children
meeting any of the following criteria at baseline or follow-up were
referred to local sources of medical care: signs and/or symptoms of
active TB, TST$5 mm and/or positive QFT-GIT (as interpreted
by assay software), positive HIV test, or age ,5 years.
Statistical considerations
Prevalence of MTB infection was defined as having a positive
test result at baseline and/or 6 months by TST or QFT-GIT. For
the primary analysis and from an operational perspective for study
implementation, a TST conversion at 6 months was defined as
having a negative TST at baseline, with a TST$5 mm induration
at 6 month follow-up. QFT-GIT conversion was defined as having
a negative or indeterminate QFT-GIT at baseline, with a positive
QFT-GIT at 6 months follow-up. South African guidelines
currently suggest a TST$10 mm is positive in children. They
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clinical history suggests contact with an active TB case [5].
Secondary analyses thus explored the following additional
definitions of TST conversion: 1) baseline TST,5 mm, and
follow-up TST$5 mm induration (least stringent); 2) baseline
TST,10 mm and follow-up TST$10 mm induration (more
stringent absolute cutoff); 3) baseline TST,5 mm and follow-up
TST increase by at least 10 mm induration (most stringent).
Secondary analyses also explored the following four definitions for
QFT-GIT conversion that have been previously proposed in the
literature [8]: 1) baseline IFN-c ,0.35 IU/ml and follow-up IFN-
c $0.35 IU/ml (i.e. negative to positive change according to
manufacturer’s criteria; least stringent); 2) baseline IFN-c
,0.35 IU/ml and follow-up IFN-c $0.35 IU/ml, plus at least a
30% increase in IFN-c over baseline value; 3) baseline IFN-c
,0.35 IU/ml and follow-up IFN-c $0.35 IU/ml, plus at least an
absolute 0.35 IU/ml increase in IFN-c over baseline value; 4)
follow-up IFN-c $0.70 IU/ml (most stringent). Concordance
between QFT-GIT and TST results was assessed using the kappa
statistic. Categorical data were compared using x
2 and McNe-
mar’s tests. Factors associated with QFT-GIT and TST results
were assessed using univariate and multivariate logistic regression
analysis, with robust variance and clustering on index cases.
Covariates included in multivariate analysis were based on
stepwise selection (p,0.3) or clinical importance (i.e. age, gender,
HIV status, index case TB status) [14]. Regression analyses were
performed separately for index case factors and pediatric factors.
Data were analyzed using STATA (version 10.1, StataCorp,
College Station, Texas).
Results
Study profile and baseline testing
A total of 169 adult index TB cases and 270 pediatric contacts
were enrolled with baseline characteristics shown in Table 1.
Results of baseline testing have been described previously [11].
Briefly, the estimated prevalence of MTB infection at baseline was
similar between QFT-GIT and TST when a 5 mm induration
cut-off for TST positivity was used (29% [79/270] vs. 28% [71/
254] for QFT-GIT and TST, respectively [p=0.49, kappa 0.58]).
When a baseline TST induration of $10 mm was considered
positive, the estimated MTB prevalence differed significantly
between the two tests (22% [57/254] vs. 29%, for TST and QFT-
GIT respectively; p=0.002; kappa 0.54).
A 6-month follow-up visit was completed for 196/270 (72.5%)
children, and the remainder were lost to follow-up (Figure S1).
There was no difference in median age, gender, nutritional status,
or BCG status between children with a follow-up visit and those
that lost to follow-up (Table 1). Similarly, there was no difference
in baseline QFT-GIT positivity rates between those that had a
follow-up visit (32% QFT-GIT positive), and those lost to follow-
up (23% QFT-GIT positive; p=0.163), though baseline TST
positivity rates were higher among children with follow-up (32%
TST positive) compared to those who were lost (16% TST
positive; p=0.009). While overall rates of HIV were low in our
study, there was a slightly higher rate of HIV infection among
those children that were lost to follow-up (7/74 [9%]) compared to
those with a 6 month visit (7/196[4%]; p=0.035).
Prevalence of TB infection in pediatric contacts at 6
months follow-up by QFT-GIT and TST
Among the 196 children who had a follow-up visit, all 196
(100%) had a repeat QFT-GIT performed, while 127 (65%) had a
TST completed at 6 months (60 children had baseline positive
TST [$5 mm] and did not have a second TST per the study
protocol). All 270 pediatric contacts had either a baseline and/or
follow-up QFT-GIT testing performed, while 263 children had
either a baseline and/or 6 month follow-up TST performed
(Figure S1).
Table 1. Characteristics of study participants at enrollment and follow-up.
Characteristic Value, as n (%) unless otherwise specified
Baseline Pediatric
Contacts N=270
Pediatric Contacts with 6
month Follow-up N=296
Pediatric Contacts Lost to
Follow-up N=74 p**
Sex Male n(%) 129 (48) 92(47) 37(50) .65
Median age (IQR) 6 (3–9) 6(3–9) 6(4–10) .23
Ethnicity, n(%) African/Black 256 (95) 123(95) 39(98) .21
Colored/Mixed 11 (4) 5(4) 1(3)
Unspecified or Other 3(1) 2(2) 0(0)
HIV, n(%) Infected 14 (5) 7(4) 7(9) .035
Uninfected 251 (93) 187 (95) 64(87)
Unknown 5 (2) 2(1) 3(4)
Median weight for age Z score (IQR)* 0.13 (20.86 to 0.97) .11 (2.83 to.93) .25(2.86 to 1.21) .89
Median weight for height Z score (IQR)* 1.3 (20.05 to 2.14) 0.94 (2.3 to 2.3) 1.3 (.09 to 2.1) .99
Median length for age Z score (IQR)* 21.44 (22.8 to 20.5) 21.2 (22.7 to 2.7) 21.6 (22.9 to 2.37) .40
BCG vaccinated per report of parent/guardian, n(%) 257 (95) 186 (95) 71(96%) .38
Baseline positive TST ($5 mm), n% 71/254{ (28) 60/185{ (32) 11/69{ (16) .009
Baseline positive QFT-GIT, n% 79 (29) 62 (32) 17 (23) .163
Abbreviations: IQR, interquarterile ratio.
*for children #60 months old.
**comparing pediatric contacts with follow-up vs. contacts that were lost.
{16 pediatric contacts did not have baseline TST results.
doi:10.1371/journal.pone.0026787.t001
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increased significantly from a baseline of 29% (79/270; 95% CI
[24–35]) to 38% (103/270, 95%CI [32–44], p,0.001; Table 2) at
six months of follow-up. There was no difference in the six-month
MTB period prevalence estimate when using more stringent
thresholds for QFT-GIT conversion (Table 2). If only the 196
children with follow-up visits were included in the analysis, the
period prevalence of MTB infection would rise from a baseline
32% (62/196, 95% CI 25–39]) to 44% (86/196,95% CI [37–51],
p,0.01) six months later.
The prevalence of MTB infection as ascertained by TST
(TST$5 mm induration) in pediatric contacts increased signifi-
cantly from a baseline of 28% (71/254, 95%CI [23–34]) to 33%
(88/263, 95%CI [21–32], p.002; Table 3) six months later. The
increaseinestimatedprevalence frombaselinetofollow-upwasseen
even when using higher thresholds for TST positivity (Table 3).
When a threshold of TST$10 mm induration was considered, the
MTB prevalence increased from a baseline of 22% (57/254, 95%
CI [17–28]) to 27% (70/263, 95% CI [21–32], p,0.001). When an
even higher threshold for TST conversion was considered (i.e.
absolute TST increase in 10 mm from baseline to follow-up), there
was still a significant increase in 6-month MTB prevalence from a
baseline of 28% (71/254, 95%CI [23–34]) to 31% (81/263 95%CI
[25–37]), p,0.01). Despite these increases, however, the overall
MTB period prevalence estimates at 6 months were significantly
lower when using the higher threshold of TST$10 mm (27%) or a
threshold requiring increase in 10 mm induration (31%), compared
to using a 5 mm cut-off (33%,Table 3). If only the children with
follow-up visits were included in the analysis, the estimated
prevalence of MTB infection ascertained by TST (TST$5m m
induration) would rise from 32% (60/185, 95%CI [26–40]) to 40%
(77/194, 95%CI [33–47], p,0.01).
The overall measured 6 month period prevalence of MTB
infection was higher by QFT-GIT (38%) than by TST (33%) in the
primary analysis (TST$5 mm threshold for positivity), but this
difference did not meet statistical significance (p=0.08). When more
stringent thresholds for TST positivity (i.e. TST$10 mm at baseline
or follow-up; TST$5m ma tb a s e li n eo ri n c re a s ei na tl e a s t1 0m ma t
follow-up) were considered, the estimated MTB prevalence was
significantly higher for QFT-GIT (using any of the 4 proposed QFT-
GIT thresholds for positivity) than for TST (Table S1).
Univariate and multivariate analysis were performed to evaluate
factors associated with a positive TST or QFT-GIT (i.e. positive at
either baseline or 6 months follow-up) and are found in Tables S2
and S3 (supplemental content). There was a significant association
between grading of adult index case smear status and a positive
QFT-GIT (AOR 6.3 [95%CI 1.1–35] and 5.4 [95%CI 1.3–23]
for 2+ and 3+ smear positivity, respectively; Table S2). Index case
age, gender, duration of cough, daytime duration of exposure, and
nighttime exposure to pediatric contacts were not associated with a
positive QFT-GIT or TST result. Of the pediatric factors that
were assessed, only age .10 years was significantly associated with
a positive QFT-GIT (AOR 3.8 [1.5–9.6]; p=0.004); no pediatric
factors were associated with a positive TST (Table S3).
Analysis of QFT-GIT conversions and reversions
Among 117 children with a negative QFT-GIT at baseline and
a test performed at follow-up, the follow-up test remained negative
for 86 (73.5%), converted to positive for 22 (18.8%), and was
indeterminate for 9 (7.7%) (Table 4). Among 62 children with a
positive QFT-GIT at baseline and a test performed at follow-up,
the follow-up test remained positive in 53 (85.5%) and reverted to
negative in 9 (14.5%). Among 17 children with indeterminate
QFT-GIT results at baseline, 13 (76%) were negative, 2 converted
to positive (15%), and 2 remained indeterminate. Overall, 24/134
(18%, 95% CI [0.12–0.25]) converted their QFT-GIT from
indeterminate or negative to positive (Tables 2 and 4). The mean
quantitative QFT-GIT result at baseline was 4.4 IU/ml with a
standard deviation of 9.5 IU/ml (median 0.18 IU/ml, IQR [0.11–
1.47]), while mean QFT-GIT result at follow-up was 4.9 IU/ml
with a standard deviation of 8.7 IU/ml (median 0.28, IQR [0.12–
5.4]).
In multivariate analysis of factors associated with QFT-GIT
conversion at follow-up, older children were more likely to have
QFT-GIT conversion than younger children (pediatric age 6–10
years AOR 6.0 [1.0–35] p=0.048; pediatric age .10 years AOR
8.9 [1.1–72] p=0.040, compared to pediatric age,2 years).
Additionally, the rate of QFT-GIT conversions among contacts
with baseline TST-positivity $5 mm (5/13, 38%) was higher
compared to those with baseline TST-negative results (15/
98[15%]; AOR 5.2 [1.2–23.4]; p=0.03). No adult index case
factors were associated with QFT-GIT conversion, including age,
Table 2. Prevalence of TB infection and incidence of conversions using QFT-GIT.
Prevalence of TB infection{ Conversions
QFT-GIT thresholds for baseline positivity and
conversion at follow-up testing Baseline n (%) 6 month n (%) p values {{{
Negative or
indeterminateBaseline
QFT-GIT n
Conversions n
(%)
Baseline or follow-up QFT-GIT $0.35 IU/ml 79/270 (29%) 103/270 (38%){{ p,0.01 134 24 (18%)u
Baseline QFT-GIT $0.35 IU/ml or Follow-up QFT-GIT
$0.35 IU/ml, plus 30% increase over baseline
79/270 (29%) 103/270 (38%){{ p,0.01 134 24 (18%)u
Baseline QFT-GIT $0.35 IU/ml or Follow-up QFT-GIT
$0.35 IU/ml, plus absolute increase of 0.35 IU/ml over
baseline
79/270 (29%) 102/270 (38%){{ p,0.01 134 23 (17%)u
Baseline QFT-GIT $0.35 IU/ml or Follow-up QFT-GIT
$0.70 IU/ml
79/270 (29%) 102/270 (38%){{ p,0.01 134 23 (17%)u
{6-month prevalence defined as a positive QFT-GIT result, at either baseline and/or follow-up. 270 children had QFT-GIT testing at baseline. 6 month QFT-GIT testing was
performed on 196 children; 134 had negative or indeterminate baseline QFT-GIT tests and were included in analysis of conversions. 74 children were lost to follow-up.
{{p.0.05 for all pair-wise comparisons.
{{{p values compare rate of baseline positivity to follow-up.
up.0.05 for all pair-wise comparisons; if only those with baseline negative results are included (i.e. exclude indeterminates), the rates of QFT-GIT conversion for all
thresholds was 22/117 (18.8%,).
doi:10.1371/journal.pone.0026787.t002
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evaluated the impact of using three other more stringent
thresholds for QFT-GIT test conversion, but we found no
statistically significant difference in incidence of conversions by
varying thresholds (Table 2). Overall, among children with QFT-
GIT conversion (follow-up QFT-GIT .0.35 IU/ml), the mean
increase was 7.5 IU/ml (median 4.07 IU/ml [IQR 1.28–10.5]).
In multivariate analysis of factors associated with QFT-GIT
reversion at follow-up, female pediatric contacts (8/33; 24%) had
higher rates of reversion from positive to negative QFT-GIT than
males (1/29; 3.5%) (AOR 18.5 [1.1–321]; p=0.04); pediatric
contacts with a positive baseline TST (2/47[4%]) were less likely
to revert from positive to negative QFT-GIT compared with those
with a negative baseline TST (7/13[54%]; AOR 0.01 [0.001–
0.24], p,0.01). No other index case or pediatric factors, including
age, were significantly associated with QFT-GIT reversion.
Overall, among those children with QFT-GIT reversions, baseline
QFT-GIT results ranged from 0.66 IU/ml to 25.9 IU/ml
(median 1.45 [IQR 1.2–3.5]).
Analysis of TST conversions
Among the 196 children with 6 month follow-up, 60 children
had baseline positive TST ($5 mm) and were not retested by
study protocol, while 127 had a second TST performed at six
months (Table 5). Among 127 children with a negative (or
unknown [n=9]) TST at baseline, the follow-up test was negative
in 110 (87.0%) and became positive ($5 mm) in 17 (13.4%).
Among these 17 TST conversions from negative (or unknown) to
positive, 4 (24%) had follow-up TST between 5–9 mm, 6 (35%)
had TST between 10–15 mm, and 7 (41%) had TST$15 mm.
Among these 17 TST conversions, mean baseline TST was
0.15 mm with standard deviation of 0.55 mm (median 0 mm,
range 0–2 mm); mean follow-up TST was 15.7 mm with standard
deviation of 8.4 mm (median 15, IQR [10–20]). When excluding
those with unknown baseline TST results, 13/118 (11%) children
converted from a negative baseline TST to a positive TST at 6
months. In secondary analysis, we compared different thresholds
for TST conversion. Conversion rates were higher when using a
simple negative to positive (i.e. from ,5m mt o$5 mm) threshold
(17/127 [13.4%]) compared to using the most stringent threshold
requiring an increase of at least 10 mm induration (10/127
[7.8%]; p=.02; Table 3). Overall, mean TST response at baseline
was 4.3 mm induration with a standard deviation of 7.7 mm
(median 0 mm, IQR [0–5]), while mean TST response at follow-
up (including baseline results if previously positive and not
retested) was 6.1 mm with a standard deviation of 8.7 mm
(median 0 mm, IQR [0–10]).
In multivariate regression analysis, only baseline QFT-GIT
positivity was associated with converting TST from negative to
positive (AOR 11.1 [1.6–76.6]; p=0.01). The rate of TST
conversion (from ,5m mt o$5 mm) among contacts that were
QFT-GIT-positive/TST-negative at baseline was 46% (6/13),
compared to 7% (6/92) among those with concordant QFT-GIT-
negative/TST-negative baseline results. No index case factors or
other pediatric factors were significantly associated with TST
conversion in multivariate regression analysis.
Concordance of TST and QFT conversions
Concordance between TST and QFT-GIT conversions is
shown in Table S4. The percent agreement in TST and QFT-
Table 3. Prevalence of TB infection and incidence of conversions using TST.
Prevalence of TB infection{ Conversions
TST Cutoffs for baseline positivity and
conversion Baseline n (%) 6 month n (%) p values {{
Negative Baseline
TST n Conversions n (%)
TST$5 mm at baseline or follow-up 71/254 (28%) 88/263 (33%)u p,0.01 127 17 (13%)**
TST$10 mm at baseline or follow-up* 57/254 (22%)* 70/263 (27%)*u p,0.01 127 13 (10%)**
Baseline TST$5 mm; Follow-up TST increase from
baseline of $10 mm
71/254 (28%) 81/263 (31%)u p,0.01 127 10 (8%)**
{6-month prevalence defined as a positive TST result, at either baseline and/or follow-up. 254 children had TST testing at baseline. Among the 16 children without
baseline TST testing, 9 had follow up testing; 263 children had a TST performed at either baseline or follow-up. 6 month TST testing was performed on 127 children
who had baseline negative TST results and were included in analysis of conversions (includes 9 children without baseline TST results). 74 children were lost to follow-
up.
{{p values compare rate of baseline positivity to follow-up.
*14 children had baseline TST induration between 5 mm and 10 mm and were classified as negative using a threshold of TST$10 mm; these children did not receive
follow-up TST per study protocol based on having TST$5 mm.
uPair-wise comparisons were made between TST thresholds. 6 month prevalence comparing TST threshold of $5 mm to threshold of TST$10 mm: p,0.001; comparing
a threshold of TST increase of $10 mm to a threshold of $5 mm: p=0.02; comparing threshold of TST increase of $10 mm to absolute threshold of $10 mm: p=0.01.
**Pair-wise comparisons were made between TST thresholds. Conversion rates comparing TST threshold of $5 mm (13%) to threshold of TST$10 mm (10%): p=0.12;
comparing a threshold of $5 mm (13%) to a threshold of TST increase of $10 mm (8%): p=0.02; comparing threshold of TST increase of $10 mm (8%) to absolute
threshold of $10 mm(10%): p=0.25.
doi:10.1371/journal.pone.0026787.t003
Table 4. Agreement of enrollment and 6 month follow-up
results by QFT-GIT–N=196*.
Enrollment Result 6-Month Follow-up Result N (%, 95%CI)
Negative Negative 86 (44, 0.37–0.51)
Negative Positive 22 (11, 0.07–0.16)
Negative Indeterminate 9 (5, 0.02–0.09)
Positive Negative 9 (5, 0.02–0.09)
Positive Positive 53 (27, 0.21–0.34)
Positive Indeterminate 0 (0)
Indeterminate Negative 13 (7, 0.04–0.1)
Indeterminate Positive 2 (1, 0.001–0.04)
Indeterminate Indeterminate 2 (1, 0.001–0.04)
*270 pediatric contacts were enrolled and 196 had follow-up visits. All 270 had
baseline QFT-GIT testing. 6 month QFT-GIT testing was performed on 196
children.
doi:10.1371/journal.pone.0026787.t004
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suggested only ‘fair’ agreement (range 0.11–0.33). The definition
of QFT-GIT conversion had little impact on concordance with
TST conversion. The highest concordance between tests was seen
when using the less stringent TST threshold of going from a
baseline of ,5 mm induration to $5 mm induration, cross-
tabulated with any of the four proposed thresholds for QFT-GIT
conversion.
TB status and treatment among pediatric contacts at 6
months follow-up
At the 6-month visit, only 57/196 (29%) children were reported
by their parent/guardian to have been started on any antimyco-
bacterial treatment since the baseline visit. Among those started on
antimycobacterial therapy, 26/57 (46%) were positive at baseline
by both TST (5 mm threshold) and QFT-GIT; 7/57 (12%) were
TST-positive and QFT-GIT- negative or indeterminate; 7/57
(12%) were TST-negative and QFT-GIT-positive; and 17 (29%)
were TST-negative with either a negative or indeterminate QFT-
GIT. Eighteen of 57 (31.5%) were on isoniazid monotherapy and
39/57 (68.4%) were on multidrug treatment for presumed active
TB. No microbiological results were available for any children.
There did not appear to be any significant association between
receipt of anti-tuberculous treatment and TST or QFT-GIT
conversions or reversions. Among 134 children with a baseline
negative/indeterminate QFT-GIT, 20/110 (18%) not receiving
any treatment had QFT-GIT conversions, while 4/24 (17%)
receiving anti-tuberculous treatment had QFT-GIT conversions
(p=0.861). Among 62 children with a positive baseline QFT-GIT
and follow-up testing available, 3/29 (10%) not receiving any
treatment reverted to a negative QFT-GIT result, while 6/33
(18%) receiving treatment reverted to a negative QFT-GIT result
(p=0.382). Among 118 children with negative baseline TST
(,5 mm), 9/97 (9%) not receiving any treatment converted their
TST to positive, while 4/21 (19%) receiving anti-tuberculous
treatment had TST conversions (p=0.195).
Discussion
Identifying pediatric TB infection remains challenging, and
children who are contacts of adult household TB cases are at
particularly high risk for infection. Consequently, the national TB
program in South Africa recommends active contact investigations
for children who are household contacts of adult pulmonary TB
cases [5]. We explored and compared the utility of follow-up TB
testing among these pediatric contacts using TST and QFT-GIT,
and found high TB prevalence rates. Importantly, we found that
the prevalence estimates of TB infection in these children
increased significantly at 6 months compared to baseline,
regardless of choice of test. When using the QFT-GIT test,
prevalence estimates increased from 29% at baseline to 38% by 6
months; similarly, prevalence increased from 28% to 33% when
using TST. These results suggest that serial testing among
pediatric contacts of adult TB cases has a higher yield in detecting
TB infection than single tests. It could not be ascertained from our
study whether test conversions from baseline to 6 months among
these children is the result of delayed development of immunologic
responses in children, or from ongoing household or community
TB exposure. However, our results underscore the fact that
limiting contact investigations to the time period immediately after
index case diagnosis may miss cases of TB infection among
pediatric contacts. While the optimal time period for follow-up
testing was not evaluated in this study, our results suggest that
serial testing six months after the initial contact investigation may
identify an increased number of pediatric contacts with M.
tuberculosis infection, compared to more limited contact investiga-
tions.
Overall, we found that the 6-month prevalence of M. tuberculosis
infection among pediatric contacts was similar as ascertained by
QFT-GIT and TST (5 mm induration cut-off). However, we
found that significantly more children would be identified with TB
infection by QFT-GIT than TST when more stringent thresholds
for TST positivity and conversion were used. In contrast, there
was little change in overall QFT-GIT prevalence results when
using alternative higher (more stringent) thresholds for QFT-GIT
test conversion, and quantitative QFT-GIT changes were robust
(mean increase 7.5 IU/ml). Concordance was highest between the
two tests when using the least stringent definition of TST
conversion (i.e. simple negative to positive change at 5 mm
induration). These observations are consistent with recently
published data suggesting impaired sensitivity of TST when using
higher thresholds for positivity (i.e. .10 mm or 15 mm indura-
tion) among children at risk for TB infection [15,16]. These results
may indicate that IGRAs are more sensitive at identifying new
infections compared to TST when higher cut-offs are used to
define TST positivity.
To date, there has been limited published information on serial
TB testing using IGRAs in children. Moreover, there has been no
consensus on whether the same cut-offs that are used for latent TB
diagnosis should also be used to define an IGRA conversion. Our
results provide important insight into QFT-GIT performance in a
high risk, heavily-exposed population that will allow better
understanding and interpretation of test results in children. Similar
studies in adult populations have suggested that IGRA conversion
rates may be dependent on the definitions and thresholds utilized
to define conversion [8,17]. In contrast, we did not find a similar
phenomenon in our population of pediatric TB contacts, even
when using more stringent criteria to define QFT-GIT conversion.
This finding leads us to postulate that these conversions in our
study were more likely to be the result of new TB infection rather
than within-person variability in IGRA responses. On the other
hand, prevalence and conversion rates ascertained by TST were
dependant on the definitions used to define positivity, making
interpretation of serial TST testing results in the context of contact
investigations more challenging.
Interestingly, we found that baseline TST and QFT-GIT
discordance was associated with test conversions on follow-up
testing. Children who were TST-positive but QFT-GIT-negative
Table 5. Agreement of enrollment and 6 month follow-up
results by TST–N=194*.
Enrollment Result 6-Month Follow-up Result N (%, 95%CI)
Negative Negative 105 (54, 0.46–0.61)
Negative Positive 13 (7, 0.04–0.11)
Negative Not Available 7 (4,0.01–0.07)
Positive Not done 60 (31, 0.24–0.38)
Not Available Positive 4 (2,0.01–.05)
Not Available Negative 5 (3, 0.01–.06)
*270 pediatric contacts were enrolled and 196 had follow-up visits. 254 had
baseline TST testing. 6 month TST was performed on 127 children; 7 children
with baseline negative TST results had study-followup, but no repeat TST results
were available; 60 children with follow-up visits had baseline TST$5m ma n d
were not retested. 74 children had no follow-up data.
doi:10.1371/journal.pone.0026787.t005
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result compared to those that were concordant TST and QFT-
GIT negative. Similarly, children with QFT-GIT-positive/TST-
negative discordance at baseline were more likely to convert to a
positive TST result at follow-up than those that were TST-
negative/QFT-GIT-negative at baseline. These findings under-
score the challenge of interpreting these tests in the absence of a
reference standard for diagnosing latent TB infection, and suggest
that neither test likely has ideal sensitivity.
IGRA reversions to negative have been previously reported and
we similarly found a relatively high rate of QFT-GIT reversions
(15%) among pediatric household TB contacts [10,17,18].
Previously, it has been suggested that some reversions may be
accounted for by minor variations in IGRA responses around the
cut-off points for positivity [8]. However, we found no reversions
among children with weakly positive baseline QFT-GIT results,
and all observed reversions in our study occurred in children with
robust baseline IGRA responses (median 1.5 IU/ml). We found
an association between female gender and reversion of QFT-GIT
results, which has not been previously reported, but it remains to
be seen if this finding is replicated in other settings. Children who
were QFT-GIT positive at baseline were also more likely to revert
to a negative QFT-GIT result at follow-up if they had a baseline
negative TST. Some have previously reported reversions or
reductions in IGRA responses following latent TB treatment
[19,20]. In contrast, we did not find a significant association
between receipt of anti-tuberculous treatment and reversion of
IGRA responses. Ultimately, whether QFT-GIT reversion
represents impaired specificity, clearing of M. tuberculosis infection
or reduced secretion of mycobacterial antigens, or a transient
variability in immunologic responses is unclear and warrants
further study.
Our study has several limitations. Six month follow-up test data
was only available on approximately 75% of children that were
initially enrolled. Our prevalence results therefore likely represent
an underestimation of the true burden of M. tuberculosis infection in
this population. Additionally, children with a positive TST result
at baseline did not receive a follow-up TST, and therefore we
could not explore factors associated with TST reversions. Also,
there was a higher rate of HIV infection among children lost to
follow-up (9%) compared to those with serial testing available
(4%), suggesting that the study may have excluded a subgroup of
sicker children. This potential selection bias could lead to
underestimation of the prevalence of M. tuberculosis infection in
this population. Finally, we did not have access to microbiological
information on study participants, and were therefore unable to
correlate TST and QFT-GIT results with mycobacterial culture
data. Nonetheless, we report treatment information for children
who presented for 6-month follow-up visits and explored the
association of MTB treatment with TST and QFT-GIT positivity.
In conclusion, the estimated prevalence of TB infection in South
Africa among pediatric contacts of adult household cases was high
using a follow-up test six months later and a strategy for contact
investigations that incorporates follow-up testing may be advisable.
Serial testing is feasible and useful in this setting, and IGRAs may
represent an alternative testing option to TST. IGRA conversions
and reversions occur frequently on serial-testing and further
studies are warranted to determine the long-term prognosis of
children who exhibit these test patterns.
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